GLSI - Greenwich LifeSciences raised $33M+ in IPO

Greenwich LifeSciences (GLSI) +4.8% PM, will virtually ring the Nasdaq opening bell on Dec.28, 2020 for recently completing its IPO."We are developing our GP2 immunotherapy to prevent breast cancer recurrences. With the IPO and follow-on offering, we have now raised over $33M, and are funded through an interim analysis and data read out of the planned Phase III clinical trial, including the submission of a Biologics Licensing Application to the FDA for conditional marketing approval of GP2," CEO Snehal Patel commented.The stock has skyrocketed 630% in the past one month trading session.BOOX Research on Seeking Alpha wrote yesterday, "Greenwich LifeSciences: Optimism On 'GP2' Breast Cancer Immunotherapy Candidate" and assigned a Neutral rating on the stock.More: Check the company's Clinical Trials section on its website for more details.

For further details see:

Greenwich LifeSciences raised $33M+ in IPO